Due to elevated cancer risk, RRBSO is recommended at the age of about 35–40 years in BRCA1 and 40–45 years in BRCA2 mutation carriers, whereby family planning and the earliest age at diagnosis in affected family members have to be taken into consideration (Wagner and Reuß 2019; The Australian Cancer Network and National Breast Cancer Centre 2004). The gene discussed is BRCA2; the disease is cancer.